News articles about ARGENX SE-ADR (NASDAQ:ARGX) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. ARGENX SE-ADR earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.2920346066203 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Several equities analysts have recently commented on ARGX shares. Zacks Investment Research lowered ARGENX SE-ADR from a “buy” rating to a “hold” rating in a research note on Wednesday, October 25th. Cowen and Company restated a “buy” rating on shares of ARGENX SE-ADR in a research note on Thursday, August 24th.
Shares of ARGENX SE-ADR (NASDAQ:ARGX) opened at 23.00 on Monday. The company’s market cap is $618.03 million. ARGENX SE-ADR has a 12 month low of $17.33 and a 12 month high of $27.25. The company’s 50-day moving average price is $23.19 and its 200-day moving average price is $21.50.
TRADEMARK VIOLATION WARNING: “ARGENX SE-ADR (ARGX) Receiving Somewhat Positive Press Coverage, Report Shows” was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.com-unik.info/2017/10/30/argenx-se-adr-argx-receiving-somewhat-positive-press-coverage-report-shows.html.
About ARGENX SE-ADR
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The companys lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
What are top analysts saying about ARGENX SE-ADR? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ARGENX SE-ADR and related companies.